CRP and rheumatoid arthritis: In our cohort, the administration of tofacitinib induced an improvement of RA disease activity, and a significant reduction of DAS28-CRP (p < 0.001) and SDAI (p = 0.011) was observed, as reported in Fig. 3A and B, respectively.